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Abstract
Diverse physiological actions of growth hormone (GH) are mediated by changes in gene
transcription. Transcription can be regulated at several levels, including post-translational
modification of transcription factors, and formation of multiprotein complexes involving
transcription factors, co-regulators and additional nuclear proteins; these serve as targets for
regulation by hormones and signaling pathways. Evidence that GH regulates transcription at multiple
levels is exemplified by analysis of the proto-oncogene c-fos. Among the GH-regulated transcription
factors on c-fos, C/EBPβ appears to be key, since depletion of C/EBPβ by RNA interference blocks
the stimulation of c-fos by GH. The phosphorylation state of C/EBPβ and its ability to activate
transcription are regulated by GH through MAPK and PI3K/Akt-mediated signaling cascades. The
acetylation of C/EBPβ also contributes to its ability to activate c-fos transcription. These and other
post-translational modifications of C/EBPβ appear to be integrated for regulation of transcription by
GH. The formation of nuclear proteins into complexes associated with DNA-bound transcription
factors is also regulated by GH. Both C/EBPβ and the co-activator p300 are recruited to c-fos in
response to GH, altering c-fos promoter activation. In addition, GH rapidly induces spatio-temporal
relocalization of C/EBPβ within the nucleus. Thus, GH-regulated gene transcription mediated by C/
EBPβ reflects the integration of diverse mechanisms including post-translational modifications,
modulation of protein complexes associated with DNA and relocalization of gene regulatory proteins.
Similar integration involving other transcription factors, including Stats, appears to be a feature of
regulation by GH of other gene targets.
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Pituitary Growth Hormone (GH) has long been known as a major regulator of normal growth
and metabolism (1-3). Among its diverse actions, GH promotes statural growth in conjunction
with Insulin-like Growth Factor 1 (IGF-1) by stimulating chondrocytes in long bones (4-7).
GH promotes a relative increase in lean body mass and decrease in body lipid, reflecting
changes that include the ability of GH to increase cellular protein synthesis, stimulate lipolysis
and impair lipogenesis under physiological conditions (8,9). GH excess can result in
acromegaly and insulin resistance (8,10,11).
GH-regulated gene transcription underlies many of the diverse responses to GH (Fig 1). These
responses are initiated by the interaction of GH with the GH receptor, a member of the cytokine
receptor superfamily (12,13). Janus kinase 2 (JAK2), a non-receptor tyrosine kinase, associates
with dimerized GH receptors (14). The activated JAK2 phosphorylates itself and the
cytoplasmic domain of the GH receptor to initiate downstream signaling. Cytoplasmic
signaling molecules, including Signal Transducers and Activators of Transcription (Stats),
pathways mediated by Mitogen Activated Protein Kinases (MAPK), and Phosphatidy Inositol
3′ Kinase (PI3K), relay GH signals to the nuclei of target cells to modulate gene transcription
(12,13,15,16).
Changes in gene transcription in response to GH occur at multiple levels, including post-
translational modifications of nuclear proteins, formation of nucleoprotein complexes and
cellular relocalization of factors that regulate transcription. While some aspects of these events
have been analyzed for the Signal Transducers and Activators of Transcription (Stats), this
review focuses on regulation of CCAAT/Enhancer Binding Protein β (C/EBPβ), a transcription
factor essential for GH-stimulated c-fos expression and serves to illustrate the complexity in
the diverse mechanisms of gene regulation by GH.
GH regulates transcription by modifying the activity of multiple transcription
factors
As part of the mechanism of gene regulation by GH, it has been amply demonstrated that Stat
family members, especially Stat 5a and 5b, mediate the GH-dependent activation of a number
of genes (15). Interaction of GH with its receptors activates the tyrosine kinase Jak2, which
phosphorylates and activates cytoplasmic Stats 1, 3, and 5. Phosphorylated Stats translocate
to the nucleus and bind to DNA elements within GH target genes (17). Stat 5b has been
implicated in the transcription of multiple GH-regulated genes, and in GH-promoted growth
in vivo (18,19). The gene for IGF-1, has recently been shown to be regulated by Stat 5 in
response to GH (20-25). In the case of the gene for the liver-specific serine protease inhibitor
2.1 (Spi 2.1), a component of acute phase responses (26), GH regulates transcription through
an upstream regulatory region containing a GH response element (GHRE) which binds Stat 5
at several Gamma-interferon Activated Sequence (GAS)-Like Elements (GLE) (27-29).
Studies of the genes encoding members of the cytochrome P450 (cyp) 2 and 3 families involved
in steroid metabolism demonstrate that sexually dimorphic GH secretory patterns in male and
female murine models differentially regulate gene expression through a mechanism mediated
by transcription factors Stat 5b and Hepatic Nuclear Factor (HNF) 4α (30-32).
Although Stat 5a and 5b mediate transcription of these and other GH-regulated genes, it is well
recognized that overall transcription is dependent on the coordination of multiple transcription
factors and other nuclear proteins. Some of these factors and events have been elucidated by
analysis of the proto-oncogene c-fos. This ubiquitous early response gene associated with cell
growth is rapidly and transiently induced by GH (33,34). Analyses of the c-fos enhancer region
have identified multiple transcription factors regulated by GH through multiple signaling
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pathways (16) (Figure 1). These transcription factors include Stats 1 and 3, which are induced
to bind to the Sis-Inducible Element (SIE) in response to GH (35-38). Serum Response Factor
(SRF) and Ternary Complex Factor (TCF) family members such as Elk-1 bind to the Serum
Response Element (SRE) and also mediate c-fos transcription in response to GH (39,40). The
c-fos C/EBP site, which binds the transcription factors C/EBPβ and C/EBPδ, is also regulated
by GH (16). Further, since the c-fos enhancer also contains an AP-1 site, it is of interest that
GH also induces binding of Fos and Jun family proteins to this element (41-43). Deletion
analysis of the c-fos promoter suggests that each of these transcription factor binding sites
contributes to GH-regulated c-fos promoter activation (44). GH also appears to stimulate
phosphorylation of the Cyclic AMP Response Element Binding Protein (CREB) (45) (Cui and
Schwartz, submitted), which can mediate c-fos transcription through a proximal CRE (46,
47).
A critical role for the transcription activator C/EBPβ (Fig 2A) in c-fos promoter activation by
GH was demonstrated by loss of function experiments. Expression of a short hairpin RNA
targeting C/EBPβ (siC/EBPβ) reduced endogenous C/EBPβ levels via RNA interference
(RNAi) (Fig. 2B) (48). This manipulation abolished the ability of GH to mediate c-fos promoter
activation and expression of endogenous c-fos mRNA (48). These findings indicate that cellular
C/EBPβ plays a critical role in the ability of GH to stimulate c-fos transcription.
Complementary experiments in primary murine embryonic fibroblasts (MEF) from mice with
a targeted deficiency of C/EBPβ (49,50) revealed that the absence of C/EBPβ impaired GH-
stimulated c-fos promoter activity (51) and established that endogenous C/EBPβ is necessary
for full activation of the c-fos promoter by GH. Understanding the mechanisms by which
hormones such as GH regulate C/EBPβ function is of broader interest since in addition to its
role in GH regulation of c-fos transcription, this widely distributed transcription factor interacts
with a variety of nuclear proteins (52-55), and is a key regulator of multiple developmental
programs such as adipocyte differentiation (56). This role of C/EBPβ is pertinent in the case
of GH, since differentiation of 3T3-F442A preadipocytes, one of the most sensitive in vitro
models for studying GH action, is dependent on GH (6).
GH regulates transcription factors through a variety of post-translational
modifications
The demonstration that GH activates Stats by stimulating their tyrosine phosphorylation was
a landmark in understanding GH signaling (35,36,38). The importance of other signaling events
in GH-stimulated transcription is demonstrated by observations of GH-regulated changes in
the phosphorylation state of C/EBPβ (Fig 2A). Isoelectric focusing identified at least six
different phosphorylated forms of C/EBPβ that are regulated by GH in 3T3-F442A cells (57).
A MAPK substrate site at T235 in human C/EBPβ (which corresponds to T188 in murine C/
EBPβ) is rapidly and transiently phosphorylated in response to GH in an ERK 1/2 dependent
manner (57). Mutation at that MAPK phosphorylation site of C/EBPβ almost completely
abrogates the stimulation of c-fos in response to GH (Fig 2C), indicating that phosphorylation
at the MAPK substrate site is required for GH to activate the c-fos promoter. It is notable that
while phosphorylation of C/EBPβ at T188 is rapid and transient, dephosphorylation of C/
EBPβ at a glycogen synthase kinase 3 (GSK-3) substrate site, S184 (58) occurs only after 60
minutes. The delayed dephosphorylation may be related to attenuation of c-fos transcription
and is dependent on activation by GH of PI-3K and Akt, which leads to inhibition of GSK-3
activity. Thus, regulation by GH of the phosphorylation state of C/EBPβ mediated by MAPK
and PI-3K-Akt signaling cascades is an important component of the mechanisms of GH-
stimulated transcription.
In addition to phosphorylation, a growing list of modifications, including acetylation,
methylation, ubiquitination and SUMOylation, regulate the transcriptional regulatory potential
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of multiple nuclear proteins (59). In the case of histones, combinations of such modifications
are now recognized to serve as a “histone code” written, interpreted and erased by a complex
machinery (60). The acetylation state of nuclear proteins is highly susceptible to regulation by
histone acetyltransferases (HATs) and/or histone deacetylases (HDACs). C/EBPβ interacts
with both p300 and CREB Binding Protein (CBP) (54,61) which are nuclear co-activators with
HAT activity. p300 and CBP, homologous factors identified through their respective
associations with CREB and the viral protein E1A (62-64), were among the first co-activators
characterized. The C/EBPβ sequence contains 21 lysines, and among these K39 was found to
be acetylated by p300 (Cesena T.I., Kwok RK, Schwartz J, submitted). Mutation of C/EBPβ
at K39, which is in the transcription activation domain, leads to reduction in its acetylation as
detected by immunoblotting with anti-acetyl-lysine antibody and reduces its ability to activate
transcription of a variety of promoters, including c-fos. Further, GH-stimulated c-fos
transcription is also impaired by mutation of C/EBPβ at K39 (Cesena et al., submitted),
suggesting that acetylation of C/EBPβ at K39 facilitates its ability to activate transcription in
response to GH. In addition to activating transcription by stimulating HATS, inhibiting HDACs
to maintain acetylation can also enhance c-fos transcription (65). Since some HDACs occupy
the c-fos promoter in a GH-dependent manner (Cui and Schwartz, unpublished), regulation of
HDACs in transcription complexes may be part of the mechanism by which GH regulates c-
fos transcription. SUMOylation is a post-translational modification which is often associated
with negative regulation of transcription (66)(67). SUMOylation involves the conjugation of
members of the Small Ubiquitin-Like MOdifier (SUMO) family to acceptor lysine residues in
target proteins (68). Interestingly, lysine 133 in murine C/EBPβ is SUMOylated (69-71).
Mutation of C/EBPβ at K133 elevates basal c-fos transcription to a level where it cannot be
further stimulated by GH (71), opening the possibility that desumoylation, and consequent
relief of an inhibitory effect of SUMO, may contribute to the ability of C/EBPβ to activate
transcription in response to GH. The combined influence of multiple post-translational
modifications regulated by GH on C/EBPβ, and possibly other GH-regulated transcription
factors, is likely to be a key factor in the coordinated, moment-to-moment regulation of gene
transcription by GH.
GH regulates the composition of nucleoprotein complexes that mediate gene
transcription
Our current understanding of transcription supports a mechanism in which binding of regulated
sequence-specific transcription factors, such as the GH-regulated Stats and C/EBPβ, to their
cognate response elements, provides a platform for formation of multiprotein complexes. The
complexes often include factors such as co-activators, co-repressors, HATS, HDACs,
chromatin remodeling factors and other proteins, which communicate signals from regulated
factors to the general transcription machinery (72). Some of these nucleoproteins associate via
protein-protein interactions with individual transcription factors bound to DNA at regulated
enhancer sequences (73-76). Although co-activators may contain intrinsic HAT activity or
recruit HAT activity and co-repressors often associate with HDACs, these and many other co-
regulators mediate diverse positive and negative events (77,78). C/EBPβ as well as Stat 5b
have been reported to interact with p300/CBP (54,61,79), suggesting that formation of
transcription complexes may be another mechanism by which GH regulates transcription.
Chromatin immunoprecipitation (ChIP) experiments, which analyze the occupancy of
endogenous proteins on promoter DNA in vivo, support this model since GH rapidly increases
the occupancy of endogenous C/EBPβ on the c-fos promoter in 3T3-F442A cells (Fig 3) (48).
ChIP also reveals that the occupancy of p300 on c-fos increases rapidly and transiently with
GH treatment. The GH-induced increase in occupancy of p300 is striking because it coincides
with the transient increase in c-fos transcription induced by GH (33), and is paralleled by a
GH-induced increase in occupancy of phosphorylated RNA polymerase II (Pol II), an indicator
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of activated transcription. In support of their participation in a complex in response to GH, C/
EBPβ and p300 were found to co-occupy the c-fos promoter following GH treatment. These
re-ChIP experiments (Fig 3) suggest the presence of a complex containing both C/EBPβ and
p300 on the c-fos promoter in response to GH. The increase in occupancy is accompanied by
a synergistic increase in c-fos promoter activation when C/EBPβ and p300 are co-expressed
(48). By determining the baseline transcription, the presence of p300 appears to dictate the
extent to which GH stimulates c-fos expression. The activity of GH–induced complexes is
likely to be coordinated with other GH-regulated events including post-translational
modifications. For example, the occupancy of the phosphorylated form of C/EBPβ is rapidly
and transiently increased on the c-fos promoter in response to GH (48) and was blocked by
inhibition of ERKs 1 and 2 (Cui and Schwartz, submitted). It will be of interest to determine
whether phosphorylated C/EBPβ is newly recruited to the promoter in response to GH, or
whether C/EBPβ constitutively occupying c-fos becomes phosphorylated in situ in response
to GH. In either case, it is likely that phosphorylation of C/EBPβ is part of the regulatory
mechanisms that direct recruitment of co-regulatory proteins such as p300 to the c-fos promoter
in response to GH. Similar mechanisms may contribute to the recruitment of other factors to
this and other GH-regulated genes (80). Taken together, these findings indicate that GH
dynamically regulates the composition of complexes that assemble at the promoters of GH-
regulated genes.
GH regulates the cellular localization of transcription factors
The cellular localization of gene regulatory proteins is an important determinant of
transcription. It is well established that activation of Stats 1, 3 and 5 by GH is accompanied by
their translocation from the cytoplasm to nucleus, where they activate target genes (15). In the
case of C/EBPβ, its sub-nuclear localization appears to be a regulated event (81).
Immunofluorescence analysis of the nuclear localization of C/EBPβ revealed that GH
dramatically shifts the distribution of C/EBPβ within the nucleus (82). In resting cells, C/
EBPβ is diffusely distributed in the nucleus, but within 5 min of GH treatment C/EBPβ acquires
a distinct punctate distribution that corresponds to heterochromatin, since it co-localizes with
heterochromatin protein 1α. Interestingly, C/EBPβ phosphorylated at the MAPK substrate site
was detected in heterochromatin rapidly and transiently after GH treatment. This rapid GH-
dependent re-localization was prevented when MAPK signaling was blocked, suggesting that
re-localization is triggered by activation of MAPK in response to GH. The significance of re-
localization of C/EBPβ to heterochromatin is not clear, although one can speculate that it may
involve an endogenous truncated form of C/EBPβ (LIP), which contains a MAPK substrate
site but lacks the transcriptional activation domain, and inhibits transcription. Regulation of
the distribution of C/EBPβ in the nucleus demonstrates a novel spatio-temporal level of
regulation by GH, which appears to be coordinated with a GH-induced post-translational
modification of the transcription factor.
GH regulates transcription by multiple mechanisms
GH regulates transcription by multiple mechanisms involving a variety of post-translational
modifications of transcription factors, dynamic assembly of nucleoprotein complexes and re-
localization of transcription regulatory proteins in target cells. These mechanisms apply not
only to Stat-dependent effects of GH, but are also involved in the similarly complex C/EBPβ-
dependent transcription of GH-stimulated target genes. The following model is suggested for
C/EBPβ-mediated transcription of GH regulated genes (Fig. 4): In responsive cells treated with
GH, C/EBPβ undergoes a rapid transient phosphorylation and a delayed dephosphorylation
(57,58); these events appear to be coupled sequentially to the rapid, transient activation and
delayed cessation of c-fos expression, respectively. Acetylation of C/EBPβ in its transcriptional
activation domain appears to serve an activating role in GH-stimulated transcription; these and
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other post-translational modifications of C/EBPβ can potentially be coordinated for c-fos
transcription in response to GH. Among these events, GH rapidly and transiently induces the
occupancy of C/EBPβ and the coactivator p300, and possibly other nuclear proteins such as
HDACs, as part of a complex or complexes of proteins on GH-responsive promoters that
mediate activation of transcription. GH-induced modifications in the nuclear proteins
participating in transcription complexes, as well as their re-localization in the cell, are likely
to serve as coordinating mechanisms for integrating GH signals to regulate transcription.
Similar integration involving other nuclear proteins including Stats appears to be a feature of
regulation by GH of other genes. Each component of the diverse mechanisms for GH-regulated
transcription reveals additional targets for potential therapeutic interventions in conditions such
as impaired growth, catabolic states and insulin resistance.
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Figure 1. GH signaling to the nucleus
A model of GH-regulated signaling pathways, and transcription factors that they regulate on
representative genes, is shown. The interaction of GH with GH receptors (GHR) leads to
association and activation of JAK2, initiating signaling cascades such as those mediated by
STATS, MAPK and PI3K. These signaling pathways culminate in the regulation of multiple
transcription factors on GH target genes, as described in text.
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Figure 2. C/EBPβ is regulated by GH
A. C/EBPβ is modified post-translationally at multiple sites. The C/EBPβ diagram shows
approximate regions encompassing the transcriptional activation domain, regulatory domain,
the DNA binding basic region as well as the leucine zipper dimerization domain. Multiple
phosphorylation sites are indicated (numbering for murine sequence) and the corresponding
kinases are shown above. Circled residues are GH-regulated. B. Activation of c-fos by GH
depends on endogenous C/EBPβ. Endogenous C/EBPβ was depleted by RNA interference
through expression of siC/EBPβ, in CHO cells stably expressing a GH receptor that mediates
c-fos activation (CHO-GHR). In cells expressing vector, the typical effect of GH to activate
the c-fos promoter is seen as an increase in luciferase expression (relative luciferase units). In
cells depleted of C/EBPβ by expression of siC/EBPβ, GH fails to activate the c-fos promoter,
demonstrating that endogenous C/EBPβ is necessary for the response to GH (48). C.
Phosphorylation of C/EBPβ at a MAPK substrate site is critical for GH-stimulated c-fos
promoter activation. GH stimulates the c-fos promoter when native (WT) human C/EBPβ is
expressed in CHO-GHR cells, but expression of C/EBPβ with a mutation at a MAPK substrate
site (T235) blunts the GH response (57). Responses to GH are shown as mean ± se for at least
3 experiments.
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Figure 3. GH promotes the occupancy of a complex containing both C/EBPβ and p300 at the c-
fos promoter
Chromatin immunoprecipitation (ChIP) was performed using 3T3-F442A fibroblasts, which
respond to GH via endogenous GH receptors. ChIP indicates that endogenous C/EBPβ and
p300 are rapidly recruited to the c-fos promoter in response to GH in vivo (1st IP). Both proteins
occupy the same c-fos DNA, as demonstrated by second ChIP (48).
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Figure 4. GH regulates transcription of c-fos by multiple mechanisms
The schematic illustrates regulation of transcription of c-fos by GH in a target cell. Interaction
of GH with its receptor (GHR) and activation of JAK2 initiates multiple signaling pathways
(not shown, see (16)) that regulate transcription factors on the c-fos promoter. The GH-
responsive sequences on the c-fos promoter are indicated, and the associated transcription
factors are represented in the background. Regulation of the critical transcription factor C/
EBPβ by GH illustrates the importance of post-translational modifications: Phosphorylation
(P) of C/EBPβ modulates c-fos promoter activation by GH. C/EBPβ is also acetylated (Ac) by
p300, which also contributes to activation of c-fos by GH. GH also rapidly induces the
formation of a nucleoprotein complex containing both C/EBPβ and p300, leading to co-
activation which determines a baseline for GH-stimulated c-fos expression. MAPK-dependent
phosphorylated C/EBPβ occupies the c-fos promoter in response to GH. These events coincide
with increased occupancy of phosphorylated RNA polymerase II (P-Pol II) on c-fos and
increased c-fos mRNA expression. HDACs can also participate in complexes that regulate c-
fos expression. GH can also induce the rapid subnuclear re-localization of C/EBPβ to
heterochromatin. These diverse GH-induced events involving C/EBPβ are coordinated to
induce c-fos expression in response to GH.
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